Stockreport

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Context Therapeutics Inc.  (CNTX) 
PDF PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advan [Read more]